Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
KALA BIO Inc
KALA
Healthcare
Biotechnology
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains...
numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:KALA)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(10)
•••
MikeTester
X
Post by
MikeTester
on Aug 02, 2024 10:40am
KALA Bio, Inc. (KALA): A Promising Biopharmaceutical Company
https://beyondspx.com/2024/07/31/kala-bio-inc-kala-a-promising-biopharmaceutical-company-focused-on-rare-eye-diseases/
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Jan 04, 2023 1:25pm
KALA..... Now if I had just held those 500 shares at $6
I coulda been a contendah ; )
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 29, 2022 4:10pm
KALA..... Can't halt progress ; )
Scalped the cr*p out of this today.... LoL....No skiing for me today.... made a chit ton of dough today. Still in my robe....no breakfast My scalps today were ..... ATNF FWBI HOTH KALA NUWE NVIV PALI
...more
(9)
•••
moosesdad
X
Comment by
moosesdad
on Dec 28, 2022 12:28pm
RE:KALA ..... It held and was halted and rallied
What a run !!
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 28, 2022 12:01pm
KALA .....unreal !!!!
How sweet is this? Now at congestion dating back to last May pre-reverse split I got lucky being a seller !!!!
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 28, 2022 11:52am
KALA ..... I'm rich !!!!!!!!!!!
Yeeha !
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 28, 2022 11:32am
KALA ..... It held and was halted and rallied
Cheers to the Bulls
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 28, 2022 10:34am
KALA ..... Line in the sand @ $8.70
Has to hold or watch out !!!!
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Dec 28, 2022 10:25am
KALA ....Rug Pull Time?
Maybe
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 28, 2022 4:02pm
New Press Release - Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect
-- On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 -- -- Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing, due upon FDA acceptance of KPI-012 IND --ARLINGTON, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) --...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 28, 2022 4:01pm
New Press Release - Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing
ARLINGTON, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it has entered into a...
read article.
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 09, 2022 1:10pm
KALA ...Here's song of Champions....just replace the Layla
https://www.youtube.com/watch?v=ICpxgxThG7s
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 09, 2022 10:45am
KALA ...... BTFD time anyone ?
Maybe
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 09, 2022 10:00am
KALA ..... Paytience pays off ; )
Cha F'king Ching !!!!!!!!!!!!!!!!!!!!
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Nov 09, 2022 9:54am
KALA ..... Ripping !!!!!!!!!!!!
Yeeha!!!
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >